| ￥3500 | |
| Z04028-100 | |
|
|
|
|
|
|
|
|
|
| Species | Cynomolgus | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 41.84 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 70-85 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from a 0.22 μm filtered solution in PBS，(pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized CD6, His, Cynomolgus, His Tag at 1 μg/ml (100 μL/well) on the plate. Dose response curve for Human ALCAM, hFc Tag with the EC50 of 4.4 ng/ml determined by ELISA. »
The purity of CD6, His, Cynomolgus is greater than 95% as determined by SEC-HPLC. »
CD6, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | The cell surface glycoprotein CD6 is expressed on leukocytes and mediates T cell trafficking across endothelial cell barriers. CD6 is a lymphocyte surface co-receptor physically associated with the T-cell receptor (TCR)/CD3 complex at the center of the immunological synapse. |
| Synonyms | CD6; TP120; T12 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
